Patient P-03490
Therapy response
Declining
Tolerance
Improving
GI state
Deteriorating
Inflammatory state
Favorable
Nutritional resilience
Declining
Discontinuation risk
36%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S13
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- GI instability+12
- Nutritional resilience-11
- Toxicity-7
- Inflammatory activity+3
- Treatment adherence+2
What helped?
No interventions yet.
LIFE OS recommendation
Dietary Support Protocol NP-02
42%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 50% showed improvement
- median effect visible after 10 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Energy level
Daily log5.4/10
worsening · -0.4 vs previous 14 d
Stress level
Daily log4.9/10
worsening · +0.7 vs previous 14 d
Pessimism score
Daily log4/10
worsening · +0.3 vs previous 14 d
Sleep quality
Wearable42.2/100
worsening · -3.7 vs previous 14 d
Libido
Daily log4.1/10
worsening · -0.5 vs previous 14 d
HRV
Wearable58.1 ms
worsening · -3.9 vs previous 14 d
Toxicity
Blood10.9/100
worsening · +1.5 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 57 from the failing basin, 32 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -3.4 next day on high-intake days · n 18
Would not help
- AD-05 Adherence Supportonly 29% improved among 14 similar
- Keep caffeine lowGI +2.9 next day on high-intake days · n 24
- Keep lactose lowGI +2 next day on high-intake days · n 17
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-3.4supporter · 95%
- Caffeine+2.9detractor · 95%
- Lactose+2detractor · 62%
- Alcohol+0.9no signal · 23%
- Dietary fat load+0.6no signal · 18%
- Histamine load+0.3no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Autonomic recovery ↓65
- WearableResting HR 74 bpm
- Wearable2,269 steps/day
- WearableShort sleep window
- Drug metabolism and exposure ↑40
- DNACYP2D6 poor metabolizer → higher exposure
- Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer
- Inflammatory signalling ↑20
- MicrobiomeBacteroides fragilis expansion
DNA
Fictional pharmacogenomic panel
- CYP2D6 Poor metabolizerHigher exposure at standard dose
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.9 · butyrate capacity 51/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 58 ms
- Sleep
- 5.8 h
- Steps
- 2,444
- Resting HR
- 74 bpm
Daily log: GI score 37, nutritional resilience 51, adherence 92.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03105 | 41% | S12 | AD-05 | no change | 60 |
| P-03204 | 39% | S16 | AD-05 | improved | 48 |
| P-03351 | 36% | S07 | AD-05 | no change | 51 |
| P-03424 | 34% | S12 | AD-05 | improved | 41 |
| P-03482 | 34% | S05 | AD-05 | no change | 67 |
| P-03369 | 32% | S18 | AD-05 | no change | 37 |
| P-03034 | 31% | S14 | AD-05 | no change | 30 |
| P-03122 | 31% | S13 | AD-05 | no change | 40 |
| P-03158 | 31% | S17 | AD-05 | no change | 37 |
| P-03380 | 31% | S16 | AD-05 | improved | 34 |
| P-03441 | 31% | S19 | AD-05 | improved | 37 |
| P-03111 | 30% | S07 | AD-05 | no change | 48 |